Long-term trial of protection provided by adenovirus-vectored vaccine expressing the PPRV H protein.

Darpel, Karin E; Corla, Amanda; Stedman, Anna; Bellamy, Fiona; Flannery, John; Rajko-Nenow, Paulina; Powers, Claire; Wilson, Steve; Charleston, Bryan; Baron, Michael D; Batten, Carrie (2024). Long-term trial of protection provided by adenovirus-vectored vaccine expressing the PPRV H protein. NPJ vaccines, 9(98) Springer Nature 10.1038/s41541-024-00892-2

s41541-024-00892-2.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

A recombinant, replication-defective, adenovirus-vectored vaccine expressing the H surface glycoprotein of peste des petits ruminants virus (PPRV) has previously been shown to protect goats from challenge with wild-type PPRV at up to 4 months post vaccination. Here, we present the results of a longer-term trial of the protection provided by such a vaccine, challenging animals at 6, 9, 12 and 15 months post vaccination. Vaccinated animals developed high levels of anti-PPRV H protein antibodies, which were virus-neutralising, and the level of these antibodies was maintained for the duration of the trial. The vaccinated animals were largely protected against overt clinical disease from the challenge virus. Although viral genome was intermittently detected in blood samples, nasal and/or ocular swabs of vaccinated goats post challenge, viral RNA levels were significantly lower compared to unvaccinated control animals and vaccinated goats did not appear to excrete live virus. This protection, like the antibody response, was maintained at the same level for at least 15 months after vaccination. In addition, we showed that animals that have been vaccinated with the adenovirus-based vaccine can be revaccinated with the same vaccine after 12 months and showed an increased anti-PPRV antibody response after this boost vaccination. Such vaccines, which provide a DIVA capability, would therefore be suitable for use when the current live attenuated PPRV vaccines are withdrawn at the end of the ongoing global PPR eradication campaign.

Item Type:

Journal Article (Original Article)


05 Veterinary Medicine > Department of Infectious Diseases and Pathobiology (DIP) > Institute of Virology and Immunology

UniBE Contributor:

Darpel, Karin


600 Technology > 630 Agriculture




Springer Nature




Pubmed Import

Date Deposited:

04 Jun 2024 10:13

Last Modified:

05 Jun 2024 06:15

Publisher DOI:


PubMed ID:






Actions (login required)

Edit item Edit item
Provide Feedback